Citation Impact
Citing Papers
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator
2005
A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein
2007 StandoutNobel
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
2003 StandoutNobel
Restriction of PD-1 function by cis -PD-L1/CD80 interactions is required for optimal T cell responses
2019 Science
Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection
2005 StandoutNobel
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression
2013 StandoutNobel
Four-component protein nanocages designed by programmed symmetry breaking
2024 StandoutNatureNobel
Therapeutic siRNA: state of the art
2020
Lipid nanoparticle technology for therapeutic gene regulation in the liver
2020
Computational design of soluble and functional membrane protein analogues
2024 StandoutNatureNobel
Confusing signals: Recent progress in CTLA-4 biology
2015
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer
2006
Discovery of Selective Small-Molecule CD80 Inhibitors
2007
Cation–π interactions in ligand recognition and catalysis
2002
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
2007 StandoutNature
Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses
2007
The B7 family of immune-regulatory ligands.
2005
The reverse stop-signal model for CTLA4 function
2008
Spatiotemporal Basis of CTLA-4 Costimulatory Molecule-Mediated Negative Regulation of T Cell Activation
2010
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
2006 StandoutNobel
PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
2019
CTLA‐4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization
2007
The Interaction Properties of Costimulatory Molecules Revisited
2002
Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist
2012 StandoutNatureNobel
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
2015
Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
2004
The immunological synapse and CD28-CD80 interactions
2001
PTP1B as a drug target: recent developments in PTP1B inhibitor discovery
2007
Balancing co-stimulation and inhibition with BTLA and HVEM
2006
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
2004 Standout
Restoring function in exhausted CD8 T cells during chronic viral infection
2005 StandoutNatureNobel
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
2016 Standout
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
2009 StandoutNobel
Strategies for Targeting Protein–Protein Interactions With Synthetic Agents
2005
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy
2015
Checkpoint Blockade in Cancer Immunotherapy
2006 StandoutNobel
CD28 and CTLA‐4 coreceptor expression and signal transduction
2009
T-cell regulation by CD28 and CTLA-4
2001
Differential binding properties of B7-H1 and B7-DC to programmed death-1
2003
Interaction of human PD-L1 and B7-1
2008
Instruction of Distinct CD4 T Helper Cell Fates by Different Notch Ligands on Antigen-Presenting Cells
2004 StandoutNobel
B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse
2004 StandoutNobel
B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity
2003
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
2013 StandoutNobel
The B7–CD28 superfamily
2002
Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex
2020
The molecular architecture of protein–protein binding sites
2007
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Attenuating Lymphocyte Activity
2005
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Establishment of NOD-Pdcd1-/-mice as an efficient animal model of type I diabetes
2005 StandoutNobel
Pathophysiology of Human Visceral Obesity: An Update
2013 Standout
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy
2023 StandoutNobel
The structural and energetic basis for high selectivity in a high-affinity protein-protein interaction
2010 StandoutNobel
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
2008
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
Proline Rich Motifs as Drug Targets in Immune Mediated Disorders
2012
A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION
2005
B7x: A widely expressed B7 family member that inhibits T cell activation
2003 StandoutNobel
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
2016 StandoutNobel
Different cell surface oligomeric states of B7-1 and B7-2: Implications for signaling
2005
Inhibition of CTLA-4 Function by the Regulatory Subunit of Serine/Threonine Phosphatase 2A
2002
One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA
2021 StandoutNobel
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Molecular Interactions Mediating T Cell Antigen Recognition
2003
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
2008 StandoutNobel
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
2008 StandoutNobel
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model
2012 StandoutNobel
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction
2003 StandoutNobel
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
2016 StandoutNobel
Hierarchical Regulation of CTLA-4 Dimer-Based Lattice Formation and Its Biological Relevance for T Cell Inactivation
2005
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism
2006 StandoutNobel
Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation
2004 StandoutNobel
GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
2018
Crystal structure of the receptor-binding domain of human B7-2: Insights into organization and signaling
2003
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
2007 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1–Mediated Immune Suppression
2013
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Surface Cytotoxic T Lymphocyte–associated Antigen 4 Partitions Within Lipid Rafts and Relocates to the Immunological Synapse under Conditions of Inhibition of T Cell Activation
2002
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells
2021 StandoutNobel
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
2008 StandoutNobel
The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune Responses
2002
Single dose of anti–CTLA-4 enhances CD8 + T-cell memory formation, function, and maintenance
2010 StandoutNobel
Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability
2007 StandoutNobel
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Enantioselective Total Synthesis of Nigelladine A via Late-Stage C–H Oxidation Enabled by an Engineered P450 Enzyme
2017 StandoutNobel
Works of David V. Erbe being referenced
Crystal Structure of an HSA/FcRn Complex Reveals Recycling by Competitive Mimicry of HSA Ligands at a pH-Dependent Hydrophobic Interface
2013
H6PDH interacts directly with 11β-HSD1: Implications for determining the directionality of glucocorticoid catalysis
2008
Monocyclic thiophenes as protein tyrosine phosphatase 1B inhibitors: Capturing interactions with Asp48
2006
Small Molecule Ligands Define a Binding Site on the Immune Regulatory Protein B7.1
2002
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses
2001 Nature
MP12-14 SAFETY AND EFFICACY STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNA INTERFERENCE (RNAI) THERAPEUTIC, IN ADULT AND PEDIATRIC PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)
2019
An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria
2016